Zomedica Pharmaceuticals Corp (ZOM)
$0.13
0.0003 (0.23%)
ZOM Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
127.88M
PE Ratio
-3.63
EPS
-0.036
Volume (Avg. Vol.)
699,012
Day's Range
$0.13 - $0.13
52-Week Range
$0.12 - $0.25
Dividend & Yield
N/A (N/A)
ZOM Stock Predictions, Articles, and Zomedica Pharmaceuticals Corp News
Pet Stocks Alert: What Is Going on With PETZ and ZOM Stocks Today?
Speculative pet stocks TDH Holdings and Zomedica are jumping higher in morning trading but investors should be skeptical of the moves.
Stay Away From Zomedica for These 3 Key Reasons
ZOM stock had its best days in early 2021, but now its weak financial performance fully justifies its price weakness.
Zomedica Management Finally Delivers Some Good News
Zomedica's acquisition is precisely what was needed to get ZOM stock out of its lethargy. Long-term, it could be a game-changer. Here’s why.
Zomedica Stock Will Need More Than a Change in Management to Bounce Back
While a C-suite scenery change might be good for Zomedica, the shift may not provide a similar outcome for ZOM stock.
New CEO and Acquisition Could Breathe New Life Into Zomedica
A turnaround in ZOM stock may happen sooner rather than later as Zomedica undergoes an executive-level change and builds out its business.
Zomedica Has Potential, but It’s Far Too Expensive for Now
ZOM stock can be a pet care industry leader, but it needs to make significant improvements before becoming a solid long-term play.
The Challenges for Zomedica Continue, But It Still Has Huge Potential
Cautious investors may want to hold off, as no matter what direction it goes (higher or lower), it'll do so in a big way. But if you can stomach the risk, and have patience to wait out its current troubles, ZOM stock may be an opportunity.
3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today
A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! The final day of the workweek is here and with it comes a look at the pre-market stock movers for Friday!
With the Crickets Chirping at Zomedica HQ, Why Buy the Stock?
The only word out of Zomedica in September was its announcement of a new director. That’s not the news ZOM stock needs right now.
Even 53 Cents Is Too Much for Zomedica Stock Right Now
At one point, investors loved Zomedica. But until its plans come to fruition, ZOM stock doesn't look like much of a deal.
Is Zomedica Stock Worth the Risk? Unfortunately It’s Complicated
Zomedica started selling its TRUFORMA vet diagnostic system in March, but ZOM stock won’t see upside until supplier assay issues are resolved.
Why Economic Pressure May Build Against Zomedica
Although ZOM stock banks superficially on millennials’ love for pets, brewing economic pressures may undo this catalyst.
Zomedica Continues to Execute Poorly
It's been 3.5 months since Zomedica launched Truforma. Unfortunately, due to its poor execution, ZOM stock continues to suffer.
The Time to Buy Zomedica Stock May Be Near
After its post-meme collapse, pet healthcare play ZOM stock is still pricey. Wait for it to inch closer to a more optimal entry point.
Zomedica Needs to Start Delivering Tangible Results
Zomedica has an interesting story that could work out. However, the company's inability to execute is raising key concerns about ZOM stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! It's the final day of the week and we're starting it off with a look at the biggest pre-market stock movers for Friday!
